Search PubMed⌕ Search

Biomedical subjects

H Mikawa

Publications and source records attributed to H Mikawa.

292 records · Page 17Linked to original sources
PubMedDate not supplied

Serum copper and zinc levels in epileptic children with valproate treatment.

Valproate (VPA) induces zinc (Zn) deficiency in experimental animals, but whether VPA treatment induces deterioration of serum trace metal homeostasis in humans is uncertain. We measured serum copper (Cu) and Zn levels in epileptic children treated with VPA and/or other antiepileptic drugs (AEDs). Patients treated with VPA monotherapy had significantly lower levels of serum Cu (82.2 +/- 16.6 micrograms/dl) than normal controls (97.3 +/- 23.0 micrograms/dl). Patients treated with VPA in addition to some other AED also had significantly lower levels of serum Cu (84.8 +/- 20.0 micrograms/dl). Serum Cu concentrations in patients treated with AEDs except for VPA (87.7 +/- 19.1 micrograms/dl) were not statistically different from those of control subjects. In contrast to the reported results of animal experiments, serum Zn levels were not altered in patients with VPA treatment. Although none of our patients showed any symptoms of Cu deficiency, we should pay attention to potential Cu deficiency in patients with VPA treatment.

Anticonvulsants↗
PubMedDate not supplied

Comparative effect of 100 versus 250 micrograms/m2/day of G-CSF in pediatric patients with neutropenia induced by chemotherapy.

In pediatric patients with various malignancies, the effect of two different doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on chemotherapy-induced neutropenia was examined. Each patient was treated with two courses of the same chemotherapeutic regimen. Following each course, either 100 micrograms/m2 or 250 micrograms/m2 of rhG-CSF was infused daily starting 48 hours after the cessation of chemotherapy and continuing for 14 consecutive days. A total of 29 patients (34 cycles of therapy) were eligible for the study. Both the duration of neutropenia (< 0.5 x 10(9)/l) and median days from the nadir of neutrophils to recovery, > 0.5 x 10(9)/l, were significantly shorter when 250 micrograms/m2 was given. Moreover, the nadir counts of neutrophils and the duration of fever with neutropenia were, although not significant, in favor of 250 micrograms/m2 administration. No differences were observed in the frequency and severity of side effects.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Prevention of 1-beta-D arabinofuranosylcytosine toxicity by 4-nitrobenzyl-6-thioinosine or dipyridamole in human leukemia cell lines.

The ability of the nucleoside transport inhibitors, 4-nitrobenzyl-6-thioinosine (NBTI) and dipyridamole (DP) to prevent 1-beta-D arabinofuranosylcytosine (Ara-C) toxicity was evaluated in two human leukemia cell lines, Molt 4 and HL-60. At non-toxic concentrations, DP (in Molt4 and HL-60) and NBTI (only in Molt 4) provided significant protection, whereas HL-60 was quite insensitive to NBTI. The different response of these two cell lines to NBTI and DP was also noted in the toxicity of other nucleoside analogs, including 9-beta-D arabinofuranosyladenine (Ara-A), 2'-chlorodeoxyadenosine (CdA), tubercidin and 5'-bromodeoxyuridne (BUdR). A transport study of [3H]-Ara-C revealed that NBTI partially inhibited the drug entry into HL-60 cells, which correlated well with Ara-CTP generation.

Arabinofuranosylcytosine Triphosphate↗